The United Kingdom Clinical Pharmacy Association has voiced “grave concerns” over the withdrawal of diabetes treatment Mixtard 30.
The UKCPA insisted that the removal of Mixtard 30 was “unsettling” for patients and would incur cost to the NHS.
“NovoMix 30 (one of the likely alternative insulin choices) is more expensive than Mixtard 30, so it will impact heavily on drugs budgets throughout the healthcare community," UKCPA Diabetes Groups chair, Natasha Jacques, said.
Mixtard 30 is available as an Innolet injecting advice, which means patients with visual impairments could self administer their treatment, although UKCPA warned that alternatives were not available in this format.
The body said it had registered concerns with Mixtard 30 manufacturer Novo Nordisk, which plans to discontinue the product from December this year.
